AUS
NZ
UK
CA
USA
IND
Small-cap stocks have been resilient in recent market conditions, with indices like the S&P 600 showing signs of recovery from previous downturns. As central banks adjust interest rates and inflation data fluctuates, some of these smaller companies have drawn attention due to insider buying activity. This article highlights three Small-Cap Stocks across various sectors—biotechnology, consumer goods, and electrical construction—that have seen insider share purchases, a sign of confidence from those closely connected to the companies.
Advantage Solutions (NASDAQ:ADV)
Advantage Solutions is a provider of outsourced sales, marketing, and technology services to consumer goods companies and retailers. The company has a market capitalization of approximately $1.55 billion and operates with gross profit margins ranging between 13.28% and 23.28%. Operating expenses are primarily allocated to general and administrative costs as well as depreciation and amortization.
In the second quarter of 2024, Advantage Solutions reported sales of $873 million, along with a net loss of $101 million. Despite these financial hurdles, the company has been undergoing a strategic rebranding, positioning itself as a comprehensive retail solutions provider. Recent insider buying activity, with 6 million shares purchased between April and July 2024 for $22.07 million, has drawn attention to the stock.
MYR Group (NASDAQ:MYRG)
MYR Group specializes in electrical construction services, focusing on commercial and industrial projects as well as transmission and distribution services. The company reported net income of $49.22 million for the period ending September 16, 2024, supported by a gross profit margin of 8.83%. Operating expenses totaled $248.84 million during this period, with general and administrative expenses accounting for $242.14 million.
MYR Group's second-quarter earnings report showed a decline in sales, from $888.62 million in 2023 to $828.89 million in 2024, alongside a net loss of $15.28 million. However, insider buying activity has remained steady, with the company repurchasing 117,422 shares for $16.26 million between May and June 2024. The company has expressed plans to leverage its strong balance sheet for potential acquisitions and organic growth in the coming months.
Genus (OTC:GENSF)
Genus, a biotechnology company specializing in animal genetics, focuses on developing advanced breeding products for livestock. The company operates mainly through its Genus ABS and Genus PIC divisions, reporting revenues of £314.9 million and £352.5 million, respectively. As of March 2024, Genus had a gross profit margin of 68.02%, though this has varied, with margins as low as 36.25% in December 2023. R&D expenses remain a significant portion of its cost structure, with spending around £93 million in recent periods.
For the fiscal year ending June 30, 2024, Genus reported sales of £668.8 million, a slight decline from £689.7 million the previous year. The company's net income dropped to £7.9 million from £33.3 million, reflecting a decrease in profit margins from 4.8% to 1.2%. Despite these challenges, Genus has attracted attention due to recent insider share purchases, signaling confidence in the long-term prospects of the company.
